Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$598.03 USD
-17.66 (-2.87%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $598.05 +0.02 (0.00%) 6:28 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$598.03 USD
-17.66 (-2.87%)
Updated Aug 5, 2024 04:00 PM ET
After-Market: $598.05 +0.02 (0.00%) 6:28 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Genomics Market Gains Momentum: 3 DNA Stocks in Focus
by Nabaparna Bhattacharya
Here we discuss about how Genomics creates opportunities in MedTech for investors who are keen on putting money in the healthcare space.
Top Research Reports for UnitedHealth, Walmart & AT&T
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Walmart (WMT) and AT&T (T).
Pacific Biosciences to Gain From New Genome Sequencing Tools
by Zacks Equity Research
Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.
Bio-Rad Banks on Solid Global Scenario, Competition Rife
by Zacks Equity Research
Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.
LabCorp, Unilabs Tie Up to Expand in Companion Diagnostics
by Zacks Equity Research
LabCorp (LH) continues to strengthen hold in the diagnostics space through inorganic means.
LabCorp Extends Aetna Agreement, Expands Diagnostics Business
by Zacks Equity Research
The expanded agreement enables LabCorp (LH) to serve as a preferred national laboratory to almost all of Aetna's members starting Jan 1, 2019.
LabCorp Extends UnitedHealthcare Pact, Lifts Diagnostics Arm
by Zacks Equity Research
LabCorp (LH) and UnitedHealthcare stretch links to collaborate on a variety of value-based programs.
Thermo Fisher (TMO) Gains on Latest Buyouts Despite Cost Woes
by Zacks Equity Research
Successive product launches and a marked progress in precision medicine initiatives boost Thermo Fisher's (TMO) performance.
Top Analyst Reports for Microsoft, Facebook, Intel & Boeing
by Zacks Equity Research
Today's Research Daily features new research reports on 17 major stocks, including Microsoft (MSFT), Facebook (FB), Intel (INTC) and Boeing (BA).
Thermo Fisher (TMO) Q1 Earnings Beat Estimates, '18 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Thermo Fisher (TMO) Beats on Q1 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) has launched innovative new products in the key technology platforms.
Medical Product Stock Earnings Roster for Apr 25: LH & More
by Zacks Equity Research
Let's take a look at the factors that are likely to influence the earnings results of a few MedTech bigwigs within the broader Medical universe.
What's in the Offing for Thermo Fisher (TMO) in Q1 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.
Thermo Fisher Strong on Global Business Amid Forex Woes
by Zacks Equity Research
Thermo Fisher (TMO) witnesses solid growth globally. Foreign exchange headwinds remain.
LabCorp Forms Lab-Alliance With Kentucky-Based Health Firm
by Zacks Equity Research
The multi-year, comprehensive laboratory deal to help LabCorp (LH) provide high-quality, high-value and standardized laboratory diagnostics for Appalachian Regional Healthcare.
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
Top Stock Reports for Amgen, FedEx & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Amgen (AMGN), FedEx (FDX) and Thermo Fisher (TMO).
Thermo Fisher Scientific Buys IntegenX, Widens HID Suite
by Zacks Equity Research
Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.
Thermo Fisher Grows on New Buyouts Amid Tough Competition
by Zacks Equity Research
Thermo Fisher's (TMO) acquisition of FEI Company already adds capabilities to its analytical instruments portfolio. Also, solid cash in hand enables the company to yield fat returns to investors.
Thermo Fisher (TMO) Q4 Earnings Beat on Growth in All Lines
by Zacks Equity Research
Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.
Thermo Fisher (TMO) Beats on Q4 Earnings & Sales Estimates
by Zacks Equity Research
Thermo Fisher (TMO) rides high on strength in all segments in Q4.
Why Earnings Season Could Be Great for Thermo Fisher (TMO)
by Zacks Equity Research
Thermo Fisher (TMO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?
by Zacks Equity Research
Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.
Illumina (ILMN) Ties Up With Thermo Fisher for Ion AmpliSeq
by Zacks Equity Research
Illumina (ILMN) consistently tries to enhance NGS platform.
Are Interest Rates Really Going Up?
by Sheraz Mian
The odds of interest rates going up meaningfully are not as far-fetched as many likely in the market believe.